India
· Delayed Price · Currency is INR Ajanta Pharma Statistics
Total Valuation
Ajanta Pharma has a market cap or net worth of INR 322.39 billion. The enterprise value is 316.71 billion.
| Market Cap | 322.39B |
| Enterprise Value | 316.71B |
Important Dates
The next estimated earnings date is Sunday, July 27, 2025.
| Earnings Date | Jul 27, 2025 |
| Ex-Dividend Date | Nov 6, 2024 |
Share Statistics
Ajanta Pharma has 124.89 million shares outstanding. The number of shares has decreased by -0.66% in one year.
| Current Share Class | 124.89M |
| Shares Outstanding | 124.89M |
| Shares Change (YoY) | -0.66% |
| Shares Change (QoQ) | -0.30% |
| Owned by Insiders (%) | 42.33% |
| Owned by Institutions (%) | 19.98% |
| Float | 41.84M |
Valuation Ratios
The trailing PE ratio is 35.11 and the forward PE ratio is 30.51. Ajanta Pharma's PEG ratio is 2.72.
| PE Ratio | 35.11 |
| Forward PE | 30.51 |
| PS Ratio | 6.94 |
| PB Ratio | 8.51 |
| P/TBV Ratio | 8.61 |
| P/FCF Ratio | 38.41 |
| P/OCF Ratio | 27.86 |
| PEG Ratio | 2.72 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 24.97, with an EV/FCF ratio of 37.73.
| EV / Earnings | 34.41 |
| EV / Sales | 6.81 |
| EV / EBITDA | 24.97 |
| EV / EBIT | 28.17 |
| EV / FCF | 37.73 |
Financial Position
The company has a current ratio of 2.85, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.85 |
| Quick Ratio | 1.84 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.04 |
| Debt / FCF | 0.06 |
| Interest Coverage | 54.44 |
Financial Efficiency
Return on equity (ROE) is 25.02% and return on invested capital (ROIC) is 18.95%.
| Return on Equity (ROE) | 25.02% |
| Return on Assets (ROA) | 14.61% |
| Return on Invested Capital (ROIC) | 18.95% |
| Return on Capital Employed (ROCE) | 28.08% |
| Revenue Per Employee | 5.76M |
| Profits Per Employee | 1.14M |
| Employee Count | 8,073 |
| Asset Turnover | 0.96 |
| Inventory Turnover | 1.32 |
Taxes
In the past 12 months, Ajanta Pharma has paid 2.69 billion in taxes.
| Income Tax | 2.69B |
| Effective Tax Rate | 22.60% |
Stock Price Statistics
The stock price has increased by +9.57% in the last 52 weeks. The beta is 0.24, so Ajanta Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | +9.57% |
| 50-Day Moving Average | 2,602.69 |
| 200-Day Moving Average | 2,809.87 |
| Relative Strength Index (RSI) | 44.68 |
| Average Volume (20 Days) | 142,525 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ajanta Pharma had revenue of INR 46.48 billion and earned 9.20 billion in profits. Earnings per share was 73.53.
| Revenue | 46.48B |
| Gross Profit | 35.05B |
| Operating Income | 11.28B |
| Pretax Income | 11.89B |
| Net Income | 9.20B |
| EBITDA | 12.52B |
| EBIT | 11.28B |
| Earnings Per Share (EPS) | 73.53 |
Balance Sheet
The company has 6.14 billion in cash and 509.20 million in debt, giving a net cash position of 5.63 billion or 45.07 per share.
| Cash & Cash Equivalents | 6.14B |
| Total Debt | 509.20M |
| Net Cash | 5.63B |
| Net Cash Per Share | 45.07 |
| Equity (Book Value) | 37.90B |
| Book Value Per Share | 301.59 |
| Working Capital | 18.47B |
Cash Flow
In the last 12 months, operating cash flow was 11.57 billion and capital expenditures -3.18 billion, giving a free cash flow of 8.39 billion.
| Operating Cash Flow | 11.57B |
| Capital Expenditures | -3.18B |
| Free Cash Flow | 8.39B |
| FCF Per Share | 67.21 |
Margins
Gross margin is 75.41%, with operating and profit margins of 24.28% and 19.80%.
| Gross Margin | 75.41% |
| Operating Margin | 24.28% |
| Pretax Margin | 25.58% |
| Profit Margin | 19.80% |
| EBITDA Margin | 26.94% |
| EBIT Margin | 24.28% |
| FCF Margin | 18.06% |
Dividends & Yields
This stock pays an annual dividend of 56.00, which amounts to a dividend yield of 2.20%.
| Dividend Per Share | 56.00 |
| Dividend Yield | 2.20% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 3 |
| Payout Ratio | 37.96% |
| Buyback Yield | 0.66% |
| Shareholder Yield | 1.75% |
| Earnings Yield | 2.85% |
| FCF Yield | 2.60% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 22, 2022. It was a forward split with a ratio of 1.5.
| Last Split Date | Jun 22, 2022 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
Ajanta Pharma has an Altman Z-Score of 19.82 and a Piotroski F-Score of 6.
| Altman Z-Score | 19.82 |
| Piotroski F-Score | 6 |